BLZ945 is an inhibitor of the CSF-1R kinase receptor; it exhibits immunostimulatory and anticancer chemotherapeutic activities and prevents skeletal metastasis of diseases. BLZ945 prevents turnover of tumor-associated macrophages and increases CD8+ T cell levels, limiting tumor growth in animal models of mammary carcinogenesis.
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...



































